Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab with or without ipilimumab versus placebo after nephrectomy in high-risk localized renal cell carcinoma
NL-OMON53133Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab and ipilimumab in renal cell carcinoma (RCC) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Disease-free survival. Started Mar 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON53133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53133.